Literature DB >> 31392204

Pompe disease: what are we missing?

Benedikt Schoser1.   

Abstract

Pompe disease is a multisystemic metabolic disorder caused by a deficiency of lysosomal acid alpha-glucosidase (GAA) leading to progressive accumulation of lysosomal glycogen, lysosomal swelling and rupture in all tissues of the human body. Furthermore, autophagic buildup, organelle abnormalities, and energy deficit are regularly observed. Enzyme replacement therapy has been available for patients living with Pompe disease for more than 15 years. Although our disease knowledge has grown enormously, we still have multiple challenges to overcome. Here, I will discuss unmet clinical needs, neglected or overlooked aspects of the pathophysiology, and issues related to future therapies.

Entities:  

Keywords:  Pompe disease; axial myopathy; energy metabolism; enzyme replacement therapy (ERT); fatigue; gene therapy; unmet needs

Year:  2019        PMID: 31392204      PMCID: PMC6642932          DOI: 10.21037/atm.2019.05.29

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  52 in total

1.  Adult glycogenosis II with paracrystalline mitochondrial inclusions and Hirano bodies in skeletal muscle.

Authors:  R Fernández; J M Fernández; C Cervera; S Teijeira; A Teijeiro; C Domínguez; C Navarro
Journal:  Neuromuscul Disord       Date:  1999-05       Impact factor: 4.296

Review 2.  The role of autophagy in neonatal tissues: just a response to amino acid starvation?

Authors:  Stefano Schiaffino; Cristina Mammucari; Marco Sandri
Journal:  Autophagy       Date:  2008-04-17       Impact factor: 16.016

3.  Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.

Authors:  M L C Hagemans; L P F Winkel; P A Van Doorn; W J C Hop; M C B Loonen; A J J Reuser; A T Van der Ploeg
Journal:  Brain       Date:  2005-01-19       Impact factor: 13.501

Review 4.  Glycogen autophagy in glucose homeostasis.

Authors:  O B Kotoulas; S A Kalamidas; D J Kondomerkos
Journal:  Pathol Res Pract       Date:  2006-06-16       Impact factor: 3.250

5.  Selective paraspinal muscle amyotrophy.

Authors:  P Narayanaswami; T E Bertorini; H Halford
Journal:  J Neurol Sci       Date:  2000-05-01       Impact factor: 3.181

6.  Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.

Authors:  B G H Schoser; J Müller-Höcker; R Horvath; K Gempel; D Pongratz; H Lochmüller; W Müller-Felber
Journal:  Neuropathol Appl Neurobiol       Date:  2007-06-15       Impact factor: 8.090

7.  Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.

Authors:  Beth L Thurberg; Colleen Lynch Maloney; Charles Vaccaro; Kendra Afonso; Anne Chun-Hui Tsai; Edward Bossen; Priya S Kishnani; Michael O'Callaghan
Journal:  Lab Invest       Date:  2006-10-30       Impact factor: 5.662

8.  Fatigue: an important feature of late-onset Pompe disease.

Authors:  Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

Review 9.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

10.  Impaired performance of skeletal muscle in alpha-glucosidase knockout mice.

Authors:  Reinout P Hesselink; Marchel Gorselink; Gert Schaart; Anton J M Wagenmakers; Joep Kamphoven; Arnold J J Reuser; Ger J Van Der Vusse; Maarten R Drost
Journal:  Muscle Nerve       Date:  2002-06       Impact factor: 3.217

View more
  6 in total

1.  Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases.

Authors:  Maria Paola Belfiore; Francesca Iacobellis; Emma Acampora; Martina Caiazza; Marta Rubino; Emanuele Monda; Maria Rosaria Magaldi; Antonietta Tarallo; Marcella Sasso; Valeria De Pasquale; Roberto Grassi; Salvatore Cappabianca; Paolo Calabrò; Simona Fecarotta; Salvatore Esposito; Giovanni Esposito; Antonio Pisani; Luigi Michele Pavone; Giancarlo Parenti; Giuseppe Limongelli
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

2.  Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients.

Authors:  Kristl G Claeys; Ann D'Hondt; Lucas Fache; Koen Peers; Christophe E Depuydt
Journal:  Cells       Date:  2022-01-20       Impact factor: 6.600

3.  Non-specificity of symptoms in infantile-onset Pompe disease may delay the diagnosis and institution of treatment.

Authors:  Udara Dilrukshi Senarathne; Eresha Jasinge; Sarojini Viknarajah Mohan; Samantha Waidyanatha
Journal:  BMJ Case Rep       Date:  2022-03-09

4.  Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

Authors:  P Vanherpe; S Fieuws; A D'Hondt; C Bleyenheuft; P Demaerel; J De Bleecker; P Van den Bergh; J Baets; G Remiche; K Verhoeven; S Delstanche; M Toussaint; B Buyse; P Van Damme; C E Depuydt; K G Claeys
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

Review 5.  Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.

Authors:  Naresh K Meena; Nina Raben
Journal:  Biomolecules       Date:  2020-09-18

Review 6.  Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders.

Authors:  Ming-Jen Lee; Inyoul Lee; Kai Wang
Journal:  Biomedicines       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.